More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.61B
EPS
-9.25
P/E ratio
--
Price to sales
0.44
Dividend yield
--
Beta
1.170664
Previous close
$27.68
Today's open
$27.99
Day's range
$27.55 - $28.37
52 week range
$16.70 - $31.67
show more
CEO
Damien McDonald
Employees
7802
Headquarters
Lewisville, TX
Exchange
New York Stock Exchange
Shares outstanding
57694806
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London
Dallas, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that members of the Enovis management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT (6:30 a.m. ET).
GlobeNewsWire • Nov 12, 2026

What Enovis (ENOV) Said on Its Q3 Earnings Call
Enovis NYSE: ENOV reported third-quarter sales of $559 million and raised its full-year adjusted earnings outlook, as growth in its reconstructive business and improved cash generation helped offset what executives described as a volatile market for medical procedures.
MarketBeat • Nov 7, 2026

Enovis Corporation (ENOV) Q3 2026 Earnings Call Transcript
Enovis Corporation ( ENOV ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Kyle Rose - Vice President of Investor Relations Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Ross Osborn - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Vikramjeet Chopra - BMO Capital Markets Equity Research Steven Lichtman - William Blair & Company L.L.C.
Seeking Alpha • Nov 6, 2026

ENOVIS Announces Third Quarter 2026 Results
Dallas, TX, Nov. 05, 2026 (GLOBE NEWSWIRE) -- - Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 2, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
GlobeNewsWire • Nov 5, 2026

Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.
GlobeNewsWire • Oct 8, 2026

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis ™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.
PRNewsWire • Sep 22, 2026

Insider at Medical Device Maker Buys More Than 7,500 Shares
The acquisition involved 7,598 shares at a weighted average price of $19.74 per share, representing a total investment of ~$150,000. The transaction size equals 14% of the equity stake held by the executive before the filing.
The Motley Fool • Sep 14, 2026

Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Research • Sep 3, 2026

What Makes Enovis (ENOV) a New Buy Stock
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • Sep 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Enovis Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.